ArticleJournal of inflammation research2025
Pan-Immune-Inflammation Value as a Prognostic Biomarker for Hepatocellular Carcinoma Patients Undergoing Hepatectomy.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A blood-biomarker based CTC-ALRI score predicts recurrence in hepatocellular carcinoma patients following curative resection.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hepatocellular carcinoma (HCC) poses a substantial threat to global health, characterized by its high incidence and mortality rates. This research aims to assess the prognostic value of a systematic serum inflammation index, the pan-immune-inflammation value (PIV), in patients with HCC who have undergone hepatectomy. Patients and Methods: A total of 1764 HCC patients who underwent surgery were included in the study. These patients were divided into two groups based on the median PIV value. The Cox regression model was utilized to ascertain the independent risk factors that influence the prognosis of patients. A PIV-based nomogram was constructed and its performance was evaluated by the C-index, calibration curve, ROC curve, and DCA curve. Finally, a comparison was made between the nomogram and existing staging models. Results: Patients with elevated PIV exhibited diminished OS and RFS compared to those with lower PIV. Univariate and multivariate Cox analyses revealed that PIV is an independent predictor of prognosis. The PIV-based nomogram demonstrated excellent discrimination, calibration, and clinical net benefit. The proposed nomogram outperformed the other existing staging systems, as evidenced by a higher AUC value. Conclusion: PIV exhibits potential as a prognostic factor for both OS and RFS in patients with HCC who have undergone hepatectomy. The PIV-based nomogram can serve as an additional tool in conjunction with the existing liver cancer staging system, thereby facilitating more personalized treatment decisions for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.